Appendix 2. Secondary endpoints of the study

(1) Proportion of subjects who achieved a 10-year atherosclerotic cardiovascular disease (ASCVD) risk of less than 7.5% at 24 weeks without dropout due to adverse events.

(2) 10-year-ASCVD risk change at 12 and 24 weeks compared to baseline.

(3) Ratio of subjects who achieved comprehensive lipid targets (low-density lipoprotein cholesterol [LDL-C] <70 mg/dL, non-high-density lipoprotein cholesterol [non-HDL-C] <100 mg/dL, and apolipoprotein B <80 mg/dL) without dropping out due to adverse events.

(4) Changes at 24 weeks compared to baseline for the following indicators:
   - Calculated LDL-C, HDL-C, triglyceride, non-HDL-C, apolipoprotein B, apolipoprotein A1
   - Hepatic steatosis index
   - Fatty liver index
   - Non-alcoholic Fatty Liver Disease (NAFLD) liver fat score
   - Glycosylated hemoglobin
   - Fasting plasma glucose
   - sCD36
   - Homeostasis model assessment of insulin resistance
   - Homeostasis model assessment of β-cell function